ChinaDrugStatus

Zolbetuximab

佐妥昔单抗
Brand: Vyloy / 威络益·Oncology·Last verified 2026-11-20

CLDN18.2-directed monoclonal antibody newly added to the 2026 NRDL Negotiated List (#287) for first-line CLDN18.2+ HER2- gastric/GEJ adenocarcinoma.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字SJ20240050
Initial Approval Date
Dec 25, 2024
Notice Published
Dec 31, 2024
MAH
Astellas Pharma (安斯泰来制药)
Approved Scope
First-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy.

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #287 · Class B
Agreement Period
2027-01-01 to 2028-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Restricted to first-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-based chemotherapy.
限联合含氟尿嘧啶类和铂类药物化疗用于CLDN18.2阳性、人表皮生长因子受体2(HER2)阴性的局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字SJ20240050
Powder for Injection (注射剂)
100mg/瓶
Initial Approval

First-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy.

联合含氟尿嘧啶类和铂类药物化疗,用于CLDN18.2阳性、人表皮生长因子受体2(HER2)阴性的局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。

Approved: 2024-12-25
Published: 2024-12-31
Astellas Pharma

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Added to Negotiated List

    Newly added to 2026 NRDL Negotiated List (#287, Class B, *) for first-line CLDN18.2+ HER2- locally advanced/metastatic gastric or GEJ adenocarcinoma with chemo.

    Chinese original: 新增纳入2026版谈判药品第287项(乙类,支付标准*),限一线治疗CLDN18.2阳性、HER2阴性局部晚期或转移性胃/GEJ腺癌。

    NHSA · PDF p.148Verified 2026-11-20
  2. (2024-12-25)NMPA Approval· Notice published: Dec 31, 2024

    NMPA Initial Marketing Approval (国药准字SJ20240050 · 100mg/瓶)

    First-line treatment of CLDN18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy.

    Chinese original: 联合含氟尿嘧啶类和铂类药物化疗,用于CLDN18.2阳性、人表皮生长因子受体2(HER2)阴性的局部晚期不可切除或转移性胃或胃食管交界处(GEJ)腺癌患者的一线治疗。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

注射用佐妥昔单抗dosage name(NHSA)
Vyloybrand en(WHO)
威络益brand zh(NMPA)

Primary Sources for This Record